Clinical value of early detection of circulating tumour DNA- BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor

Clinical value of early detection of circulating tumour DNA- BRAF^V600mut in patients with metastatic melanoma treated with a BRAF inhibitor

ESMO Open. 2017 Jun 21;2(2):e000173. doi: 10.1136/esmoopen-2017-000173. eCollection 2017.

Baptiste Louveau¹, Jörg Tost², Florence Mauger², Aurélie Sadoux¹, Marie-Pierre Podgorniak¹, Alexandre How-Kit³, Cécile Pages⁴, Jennifer Roux⁴, Laetitia Da Meda⁴, Céleste Lebbe^{4

5

6}, Samia Mourah^{1

5

6}

¹ Assistance Publique-Hôpitaux de Paris, Laboratoire de Pharmacogénomique, Hôpital Saint-Louis, Paris, France.
² Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA-Institut de Génomique, Evry, France.
³ Laboratory for Genomics, Fondation Jean Dausset-CEPH, Paris, France.
⁴ Département de Dermatologie, Assistance publique-Hôpitaux de Paris, Paris, France.
⁵ Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
⁶ UMR-976, INSERM, Hôpital Saint-Louis, Paris, France.

No abstract available

Keywords: BRAF inhibitors; BRAFV600 mutation; Metastatic melonoma; circulating tumor DNA.